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A recent study identiﬁed a low-frequency variant at
CCND2 associated with lower risk of type 2 diabetes, en-
hanced insulin response to a glucose challenge, higher
height, and, paradoxically, higher BMI. We aimed to repli-
cate the strength and effect size of these associations in
independent samples and to assess the underlying mech-
anism. We genotyped the variant in 29,956 individuals and
tested its association with type 2 diabetes and related
traits. The low-frequency allele was associated with
a lower risk of type 2 diabetes (OR 0.53; P = 2 3 10213;
6,647 case vs. 12,645 control subjects), higher disposition
index (b = 0.07 log10; P = 23 10211; n = 13,028), and higher
Matsuda index of insulin sensitivity (b = 0.02 log10; P = 53
1023; n = 13,118) but not fasting proinsulin (b = 0.01 log10;
P = 0.5; n = 6,985). The low frequency allele was associ-
ated with higher adult height (b = 1.38 cm; P = 6 3 1029;
n = 13,927), but the association of the variant with BMI
(b = 0.36 kg/m2; P = 0.02; n = 24,807), estimated in four
population-based samples, was less than in the original
publication where the effect estimate was biased by ana-
lyzing case subjects with type 2 diabetes and control sub-
jects without diabetes separately. Our study establishes
that a low-frequency allele inCCND2 halves the risk of type
2 diabetes primarily through enhanced insulin secretion.
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A recent study used whole-genome sequencing and
imputation techniques to identify one of the ﬁrst robust
associations between a low-frequency variant (1.47% in
Icelandic population) and type 2 diabetes (1). The effect of
the G minor allele at rs76895963 was appreciably larger
than that of known common variants (odds ratio [OR]
0.53) (1). The G allele was associated with lower fasting
glucose levels and higher insulinogenic index, suggesting
an effect on insulin secretion, but, paradoxically, was as-
sociated with higher BMI (0.56 kg/m2) (1).
Genetic associations need testing in independent
studies to ensure associations are not false positive
results and to establish an effect size less biased by
winner’s curse (regression to the mean). Once replicated,
it is then important to test the underlying physiological
mechanisms.
The apparently paradoxical association between the
diabetes protective allele and higher BMI needs further
explanation. Genetic associations that are paradoxical to
epidemiological correlations have been described before
and provide excellent targets for further investigation of
biological mechanisms (2,3). However, associations be-
tween known type 2 diabetes alleles and BMI can be bi-
ased by a form of “index event bias,” sometimes referred
to as “truncation bias,” if data sets are restricted to case or
control subjects. This form of bias has likely led to asso-
ciations between the risk allele at TCF7L2 and lower BMI
in case subjects because carriers of the risk allele do not
need to be as overweight to develop diabetes (4).
We aimed to assess whether independent samples
provide robust replication of the strength and effect sizes
of the CCND2 associations and to investigate further the
underlying mechanisms that result in a low-frequency
allele reducing the risk of type 2 diabetes but increasing
height and BMI. We genotyped the CCND2 variant in
29,956 individuals and tested its association with risk
of type 2 diabetes and with measures of insulin sensitivity
and insulin secretion.
RESEARCH DESIGN AND METHODS
We genotyped the low-frequency CCND2 variant
(rs76895963) in 29,496 individuals of European origin.
Study characteristics and genotyping details are in Table 1.
Call rates in all samples exceeded 95%, with no evidence of
departure from Hardy-Weinberg equilibrium (P . 0.05).
We tested the association of the low-frequency variant
with risk of type 2 diabetes, diabetes-related intermediate
traits (fasting glucose, 2-h oral glucose tolerance test
[OGTT] glucose, Matsuda index of insulin sensitivity,
insulinogenic index, disposition index of b-cell function,
and proinsulin levels), BMI, fat percentage, and height.
We used Matsuda index as a surrogate index of periph-
eral insulin sensitivity, which is highly correlated (r = 0.7)
with the gold standard measure of insulin resistance
(euglycemic-hyperinsulinemic clamp [M value]) (5).
We calculated the following:
Matsuda index of insulin sensitivity
1; 000ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Ins03Gluc03 Ins0 þ Ins30 þ Ins1203 3
Gluc0 þ Gluc30 þ Gluc120
3
q
Insulinogenic index
Ins302 Ins0
Gluc302Gluc0
where Ins0, Ins30, Ins120, Gluc0, Gluc30, and Gluc120 are
insulin and glucose levels at 0, 30, and 120 min of the OGTT,
respectively. We also calculated insulin disposition index as
follows: Matsuda index of insulin sensitivity 3 insulinogenic
index.
To provide additional statistical power to estimate the
effect of the variant on BMI, we genotyped the variant in
6,597 female participants with prepregnancy BMI data
from the Avon Longitudinal Study of Parents and
Children (ALSPAC) (6). Ethics approval for the study
was obtained from the ALSPAC Ethics and Law Commit-
tee and the local research ethics committees. The ALSPAC
Web site contains details of all the data that are available
through a fully searchable data dictionary (7).
To increase our statistical power to estimate the effect
of the low-frequency variant on Matsuda index, insulino-
genic index, and disposition index, we included 5,114
samples from the Inter99 study that was part of the
original discovery (1,8). The Danish study was approved by
the ethics committee of the Capital Region of Denmark.
Diabetes-related intermediate traits were log10 trans-
formed. We used age, sex (and age squared for height and
BMI), and, if applicable, measures required to correct for
genetic background, as covariates. We assumed an addi-
tive genetic model.
Analyses of glycemic traits, Matsuda index, insulinogenic
index, and disposition index were performed in individuals
without diabetes. For BMI, we limited analyses to studies
most representative of the general population, with no or
limited enrichment for or against type 2 diabetes. For the
Genetics of Diabetes Audit and Research in Tayside Scotland
(GoDARTS), a diabetes case-control study, we randomly
selected a subset of case subjects to include with all the
control subjects such that the “population” consisted of 5%
with type 2 diabetes and 95% control subjects. We also rean-
alyzed data from the population-based studies from the orig-
inal study but without separating individuals with diabetes
from individuals without and assessed the extent of enrich-
ment for diabetes in the deCODE population-based study.
We performed ﬁxed-effects inverse variance-weighted
meta-analysis in R (9). Evidence of between-study heterogene-
ity was assessed using the Cochran Q test and the I2 statistic
(10). The study complies with the Declaration of Helsinki.
RESULTS
The CCND2 Low-Frequency Allele Is Associated With
a Lower Risk of Type 2 Diabetes
The frequency of rs76895963[G] was 1.97% in GoDARTS
(Scottish), 2.15% in Metabolic Syndrome In Men (METSIM)
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(Finnish), 1.51% in Relationship between Insulin Sen-
sitivity and Cardiovascular disease (RISC) (European
wide), and 2.04% in ALSPAC (southwest U.K.). The
rs76895963[G] allele was associated with a lower risk of
type 2 diabetes with an effect size very similar to that
described in the initial discovery study (OR unadjusted
for BMI 0.53 [95% CI 0.45, 0.63], P = 2 3 10213, OR
adjusted for BMI 0.49 [0.40, 0.58], P = 2 3 10214;
6,647 case vs. 12,645 control subjects) (Table 2 and
Fig. 1). Meta-analysis with 12,939 case and 70,909 control
subjects from the discovery studies revealed no evidence of
heterogeneity of effect size across ﬁve studies (OR unad-
justed for BMI 0.53 [0.48, 0.59], P = 1 3 10230, OR ad-
justed for BMI 0.47 [0.42, 0.53], P = 13 10235; 19,586 case
vs. 83,554 control subjects; heterogeneity P = 0.9 for both
unadjusted and adjusted model) (Table 2 and Fig. 1).
The CCND2 Low-Frequency Allele Is Associated With
Higher Insulin Secretion
The G minor allele was associated with lower fasting glucose
(b = 20.02 log [95% CI 20.02, 20.01], P = 5 3 1025; n =
11,739) and lower 2-h OGTT glucose (b =20.05 log [20.08,
20.03], P = 6 3 1025; n = 8,261). The combined meta-
analysis estimated 20.01 log [20.02, 20.01] lower fasting
glucose levels (P = 9 3 1028; n = 23,503) and 20.04 log
[20.05,20.02] lower 2-h OGTT glucose levels (P = 13 1024;
n = 13,161) per copy of type 2 diabetes protective allele
(Table 2).
The type 2 diabetes protective allele was associated
with improved ability to secrete insulin in response to
a glucose challenge test: higher insulinogenic index (b =
0.06 log10 [95% CI 0.03, 0.09], P = 1 3 1024, n = 8,067;
and b = 0.05 log10 [0.03, 0.07], P = 83 1026, n = 13,181
Table 2—Association of rs76895963 in CCND2 with type 2 diabetes, diabetes-related intermediate traits, and anthropometric
traits
Trait/disease Study Effect size 95% CI P N I2 (%) Phet
Type 2 diabetes
(BMI adjusted) (OR) Original study 0.46 0.40, 0.54 6 3 10223 12,939 vs. 70,909†† 0 0.7
Current study 0.49 0.40, 0.58 2 3 10214 6,647 vs. 12,645†† 0 0.6
Combined 0.47 0.42, 0.53 1 3 10235 19,586 vs. 83,554†† 0 0.9
Type 2 diabetes
(BMI unadjusted) (OR) Original study 0.53 0.46, 0.61 8 3 10219 12,939 vs. 70,909†† 0 0.7
Current study 0.53 0.45, 0.63 2 3 10213 6,647 vs. 12,645†† 0 0.7
Combined 0.53 0.48, 0.59 1 3 10230 19,586 vs. 83,554†† 0 0.9
Fasting glucose (log) Original study 20.01 20.02, 20.01 3 3 1024 11,764 NA NA
Current study 20.02 20.02, 20.01 5 3 1025 11,739 0 0.9
Combined 20.01 20.02, 20.01 9 3 1028 23,503 0 0.8
2-h OGTT (log) Original study 20.02 20.04, 0.01 0.15 4,900 NA NA
Current study 20.05 20.08, 20.03 6 3 1025 8,261 0 0.6
Combined 20.04 20.05, 20.02 1 3 1024 13,161 44 0.2
Matsuda index (log10)† Current study 0.02 0.01, 0.03 5 3 1023 13,118 0 0.8
Disposition index (log10)† Current study 0.07 0.05, 0.09 2 3 10211 13,028 0 0.7
Insulinogenic index (log10)† Current and
original study
0.05 0.03, 0.07 8 3 1026 13,181 0 0.5
Fasting proinsulin (log10)* Current study 0.01 20.01, 0.02 0.5 6,985 NA NA
30-min proinsulin (log10)* Current study 20.01 20.02, 0.01 0.3 6,947 NA NA
120-min proinsulin (log10)* Current study 20.01 20.02, 0.00 0.1 6,978 NA NA
BMI (kg/m2) Population-based
studies**
0.36 0.06, 0.65 0.02 24,807 0 0.8
Current study*** 0.05 20.21, 0.30 0.7 22,464 0 0.7
Combined 0.25 0.08, 0.43 4 3 1023 109,492 2 0.4
Fat mass % (log10) Current study 0.00 20.01, 0.01 0.5 6,979 NA NA
Height (cm) Original study 1.16 0.83, 1.50 6 3 10212 78,236 0 0.7
Current study 1.38 0.92, 1.84 6 3 1029 13,927 0 0.6
Combined 1.24 0.97, 1.51 2 3 10219 92,163 0 0.8
Analysis of diabetes-related intermediate traits and height reported in the table were performed in individuals without diabetes. NA, not
applicable because data from only one study were available; Phet, heterogeneity P value. *Values were adjusted for corresponding
insulin measurements at the same time points during OGTT. **Results from population studies with no apparent enrichment for or
against type 2 diabetes, including three studies from the original publication (Iranian TLGS study, Danish Inter99 study, and Danish
Health2006 study) and ALSPAC. ***To avoid index event bias or truncation bias, we used our population-based studies. (See RESEARCH
DESIGN AND METHODS and DISCUSSION.) †For insulinogenic index, we give the meta-analysis results including data presented in the original
article from the Inter99 study. For Matsuda index and disposition index, we give the meta-analysis results including a new analysis of the
Inter99 study not previously presented. ††Number of cases vs. controls.
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including the original study) (Table 2). The low-frequency
allele was associated with higher disposition index (b =
0.08 log10 [0.05, 0.11], P = 1 3 1027; n = 8,050). Dispo-
sition index was not presented in the original study, but
we analyzed the Danish Inter99 study and meta-analyzed
with METSIM and RISC, which provided an effect of 0.07
log10 [0.05, 0.09] with higher disposition index (P = 2 3
10211; n = 13,028) (Table 2).
The G allele was not associated with any measures of
proinsulin levels adjusted for corresponding insulin
levels at the same time points during OGTT (Table 2).
The analysis of the CCND2 low-frequency allele and
the Matsuda index in METSIM and RISC produced
a borderline result (b = 0.03 log10 [95% CI 0, 0.05],
P = 0.05; n = 8,134). A meta-analysis of all 13,118
individuals without diabetes from METSIM, RISC, and
Danish Inter99 resulted in a small association with
Matsuda index (b = 0.02 log10 [0.01, 0.03], P = 5 3
1023) (Table 2).
The Effect Size of the CCND2 Low-Frequency Allele
With Height Is Consistent With the Original Study
The G minor allele was associated with higher adult height
(b = 1.38 cm [95% CI 0.92, 1.84], P = 6 3 1029; n =
13,927) (Table 2). The combined meta-analysis including
data from the original study estimated 1.24 cm [0.97,
1.51] higher height per copy of the type 2 diabetes pro-
tective allele (P = 2 3 10219; n = 92,163) (Table 2).
The Effect Size of the CCND2 Low-Frequency Allele
With BMI Is Lower Than Reported in the Original Study
The original report found an association between the low-
frequency CCND2 allele and higher BMI (0.56 kg/m2) an-
alyzed separately in individuals with or without type 2
diabetes resulting in spurious associations resulting
from index event biases. To further test the BMI associ-
ation, we ﬁrst showed that individuals from the deCODE
study with both CCND2 genotype and BMI available had
a slight excess for diabetic cases (Supplementary Fig. 1).
We showed that this type of enrichment in population
studies results in a bias toward an association between
the protective allele and lower BMI because the diabetes
case subjects tend to be heavier and carry less protective
alleles than individuals without diabetes (Supplementary
Fig. 2). We thus decided to focus our analysis of the BMI
association to the four population studies with no apparent
enrichment for or against type 2 diabetes, i.e., three studies
from the original publication (the Iranian Tehran Lipid and
Glucose Study [TLGS] [n = 8,658], the Danish Inter99 study
[n = 6,228], and the Danish Health2006 study [n = 3,324])
and ALSPAC (n = 6,597). This resulted in a smaller effect of
the variant on BMI than reported in the original publication
Figure 1—Forest plot of the association between the CCND2 rs76895963 low-frequency allele and type 2 diabetes (unadjusted for
BMI) in discovery and replication studies. The dashed line indicates null effect. The top, middle, and bottom diamonds represent the
effect size (center of diamond) and 95% CIs (horizontal ends) from the discovery studies, replication studies, and overall meta-
analysis, respectively.
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(b = 0.36 kg/m2 [95% CI 0.06, 0.65], P = 0.02; n = 24,807)
(Table 2). We observed no heterogeneity between the
effect estimates between these four population-based
studies (heterogeneity P = 0.8) (Table 2). This analysis
represented our least biased estimate of the effect
size. When we combined results from the four studies
included in the original publication (reanalyzed includ-
ing both type 2 diabetes case and control subjects)
with results from four studies added in this article
(with GoDARTS individuals sampled so as to include
only 5% diabetes case subjects), the association with
BMI was present but with lower effect size (b = 0.25
kg/m2 [0.08, 0.43], P = 4 3 1023; n = 109,492) (Table 2
and Fig. 2) and with some evidence of heterogeneity
(P = 0.03).
We found no association with fat mass percentage (b =
0.00 [95% CI 20.01, 0.01], P = 0.5; n = 6,979 individuals
without diabetes) (Table 2).
DISCUSSION
Our study provides robust replication of the relatively
large protective effect of a low-frequency variant at
CCND2 against risk of type 2 diabetes and its association
with improved insulin secretion and higher height. The
estimate of the effect size on risk of type 2 diabetes in our
study was very close to that of the discovery studies and
therefore conﬁrms an unbiased estimate of the effect size:
carriers of the low-frequency allele are at approximately
half the risk of type 2 diabetes compared with noncar-
riers. Our results, together with data from the original
study, provide very strong evidence of the mechanism
of diabetes protection. The associations with improved
disposition index and insulinogenic index but smaller
effects with the Matsuda index, in up to 13,118 individ-
uals, show that the protective diabetes effect operates
primarily through a mechanism of relatively favorable in-
sulin secretory response to a glucose challenge and to
lower blood glucose more effectively than noncarriers.
The effect is unlikely to act through improved insulin
processing, as we saw no association with proinsulin lev-
els in the METSIM study, despite previous observations of
associations between the TCF7L2 and other diabetes risk
alleles in this study (2).
Our data suggest that the association between the
CCND2 protective variant and higher BMI is lower than
that previously reported. A reanalysis of previous data,
together with new data, provided evidence of an associa-
tion between the CCND2 protective allele and higher BMI,
but we observed a smaller effect and heterogeneity be-
tween studies. Determining the true biological effect of
the variant on BMI was very difﬁcult because of “index
event” bias. The “index event” in this case was a classiﬁca-
tion of normoglycemia; therefore, people carrying a type 2
diabetes protective allele remain normoglycemic at higher
Figure 2—Forest plot of the association between the CCND2 rs76895963 low-frequency allele and BMI including eight studies with no, or
limited, ascertainment or enrichment for or against type 2 diabetes. These eight studies included four from the original article, including
deCODE individuals and a sample of GoDARTS individuals made to consist of 5% diabetes case subjects. The dashed line indicates null
effect. The top, middle, and bottom diamonds represent the effect size (center of diamond) and 95% CIs (horizontal ends) from the
discovery studies, replication studies, and overall meta-analysis, respectively.
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BMIs. Similar such likely biases have been observed be-
tween strong diabetes risk alleles and BMI where the risk
allele at TCF7L2 was associated with lower BMI in indi-
viduals with type 2 diabetes because individuals carrying
a risk allele will develop diabetes at lower BMIs than non-
carriers on average (4,11). Index event bias means it is
extremely difﬁcult to determine whether diabetes risk
alleles have biological effects on BMI.
In summary, we replicated the diabetes and height
growth effects of the low-frequency variant at CCND2 in
29,956 individuals. Our best estimate of the effect of
the variant on BMI suggests that the effect is smaller
than reported in the original publication owing to index
event bias. Further studies are needed to establish the
size of the BMI association. Our data, together with the
original ﬁnding, show a mechanism through improved
insulin secretion, which results in lower fasting glucose
levels, lower 2-h OGTT glucose levels, and a lower risk of
type 2 diabetes. Combining all data including 19,586
type 2 diabetes case and 83,554 control subjects from
the original study and our study provides evidence that
carrying this variant reduces the risk of type 2 diabetes
by ~50% relative to noncarriers.
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